Phase 4 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with chronic (long-term, stable) coronary artery disease, where one or more of the major blood vessels supplying the heart has at least 50% blockage, confirmed by a CT scan or angiogram (an X-ray of the heart's arteries)
- People whose doctors have determined that opening or bypassing the blocked artery with a procedure is not a suitable option for them
- People who are able to give their informed consent to participate
Who may not be able to join:
- People who have had a sudden, severe heart event such as a heart attack (acute coronary syndrome)
- People who have previously had a procedure to open a blocked artery (such as a stent) or heart bypass surgery
- People who have a significant blockage (50% or more) in the left main coronary artery, which is a particularly critical heart vessel
- People who must take aspirin as part of their current treatment
- People who are already taking blood-thinning medications other than aspirin
- People who have an irregular heart rhythm called atrial fibrillation
- People who have had a stroke within the past six months
- People who are planned to have a major operation that would require them to stop taking aspirin
- People for whom aspirin is medically unsuitable or unsafe
- People whose doctors expect their overall health to result in a life expectancy of one year or less
- Women who could become pregnant, or women who have a positive pregnancy test at the time of joining the trial
- People whose treating doctor considers them unsuitable for the study for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Takeshi Kimura, MD, PhD, Kyoto University, Graduate School of Medicine
Phone: +81-75-751-4255
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Composite cardiovascular events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.